Congratulations to MSD, known as Merck & Co., Inc. in the U.S. and Canada, for receiving approval from the FDA for ZEPATIER™ (elbasvir / grazoprevir) for the treatment of adult patients with chronic hepatitis C virus, genotypes 1 or 4. ZEPATIER™ is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. Elbasvir blocks the viral protein NS5A, which the virus needs to reproduce and at other stages of infection. Grazoprevir blocks the viral enzyme NS3/4A protease, which enables the hepatitis C virus to survive and to replicate in host cells.
WuXi assisted in the development of elbasvir using its open-access integrated platform. MSD is a long-term partner of WuXi, and we are pleased to have helped bring this innovative drug to hepatitis C patients.